

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### The effect of natural medicine product (MOCOZIFT®) on clinical manifestations and para clinical features in patients with COVID-19: a randomized clinical trial

#### Protocol summary

##### Study aim

The effect of natural medicine product (MOCOZIFT®) on clinical manifestations and para clinical features in patients with COVID-19: a randomized clinical trial

##### Design

Forth phase of a randomized controlled triple blind clinical trial with 184 participants. Randomization was done by software

##### Settings and conduct

Patients referred to Masih Daneshvari hospital in Tehran with laboratory confirmed 2019-nCoV infection with similar treatment regimen enter the trial after signing the informed consent form. Participants will be randomly divided in two groups; intervention group which receive Remdesivir and MocoziFT syrup and control group receiving Remdesivir and placebo for five days. Vital signs, blood cell differentiation also severity of dyspnea, cough, anorexia and fatigue will be assessed by standard tests and questionnaires, before intervention and in the fifth day of intervention. Finally the results will be analyzed using SPSS software. This study is a triple blind clinical trial and patients, outcome assessor and data analyst will be blind to the contents of products.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: age older than 18 years, patients with COVID-19, prescription of Remdesivir for outpatient use, avoiding use of other traditional medicines or supplements, signing the informed consent form and exclusion criteria: participation in other clinical trials, history of hypersensitivity to natural or herbal products

##### Intervention groups

1. Patients receiving Remdesivir and MocoziFT syrup
2. Patients receiving Remdesivir and placebo

##### Main outcome variables

Cough severity, dyspnea severity, appetite, fatigue severity

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20221019056241N1**

Registration date: **2022-10-24, 1401/08/02**

Registration timing: **prospective**

Last update: **2022-10-24, 1401/08/02**

Update count: **0**

##### Registration date

2022-10-24, 1401/08/02

##### Registrant information

##### Name

Behnaz Najafi

##### Name of organization / entity

Behdane baran pharmaceutical company

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 6657 6805

##### Email address

najafi\_b90@yahoo.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2022-11-01, 1401/08/10

##### Expected recruitment end date

2023-03-20, 1401/12/29

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

### Scientific title

The effect of natural medicine product (MOCOZIFT®) on clinical manifestations and para clinical features in patients with COVID-19: a randomized clinical trial

### Public title

The effect of Mocoziift® syrup on patients with COVID-19

### Purpose

Treatment

### Inclusion/Exclusion criteria

#### Inclusion criteria:

Age older than 18 years Confirmed COVID-19 infection using PCR test Prescription of Remdesivir for outpatient use Avoiding use of other traditional medicine or supplements during the trial signing the informed consent form

#### Exclusion criteria:

Participating in other clinical trials History of hypersensitivity reactions to natural or herbal medicines

### Age

From **18 years** old

### Gender

Both

### Phase

4

### Groups that have been masked

- Participant
- Outcome assessor
- Data analyser

### Sample size

Target sample size: **184**

### Randomization (investigator's opinion)

Randomized

### Randomization description

The randomization is done using computer software (two computer-generated random lists). In this way, each individual is assigned a unique code and is attached to drug packages that will help the blind process.

### Blinding (investigator's opinion)

Triple blinded

### Blinding description

In this three-blind study, patient and clinical outcome assessor and data analyst do not have any type of data and medications. The drugs are encoded and placed on the patient and medical personnel.

### Placebo

Used

### Assignment

Parallel

### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Shahid Beheshti University of Medical Sciences

##### Street address

Darabad Ave., Bahonar St. (Niavaran)

##### City

Tehran

##### Province

Tehran

##### Postal code

1956944413

#### Approval date

2022-05-19, 1401/02/29

#### Ethics committee reference number

IR.SBMU.NRITLD.REC.1401.020

## Health conditions studied

### 1

#### Description of health condition studied

COVID-19 infection

#### ICD-10 code

B34.2

#### ICD-10 code description

Coronavirus infection, unspecified

## Primary outcomes

### 1

#### Description

The score of dyspnea severity according to Modified Medical Research Council Dyspnea Scale

#### Timepoint

One day before medicinal intervention and fifth day of intervention

#### Method of measurement

Modified Medical Research Council Dyspnea Scale

### 2

#### Description

Cough severity

#### Timepoint

One day before medicinal intervention and fifth day of intervention

#### Method of measurement

Cough visual analogue scale

### 3

#### Description

Appetite

#### Timepoint

One day before medicinal intervention and fifth day of intervention

#### Method of measurement

Simplified Nutritional Appetite Questionnaire (SNAQ)

#### 4

**Description**

Fatigue severity

**Timepoint**

One day before medicinal intervention and fifth day of intervention

**Method of measurement**

Fatigue Severity Scale (FSS)

**Secondary outcomes**

empty

**Intervention groups**

#### 1

**Description**

Intervention group: patients in this group use 5 milliliters of natural product (brand name: Mocozipt) produced in Behdane Baran pharmaceutical company, three times a day for five days

**Category**

Treatment - Drugs

#### 2

**Description**

Control group: patients in this group use 5 milliliters of placebo three times a day for five days

**Category**

Placebo

**Recruitment centers**

#### 1

**Recruitment center****Name of recruitment center**

Masih Daneshvari Hospital

**Full name of responsible person**

Babak Daneshfard

**Street address**

Darabad Ave., Bahonar St. (Niavaran)

**City**

Tehran

**Province**

Tehran

**Postal code**

1956944413

**Phone**

+98 21 2712 3000

**Email**

pr.nritld@sbmu.ac.ir

**Sponsors / Funding sources**

#### 1

**Sponsor**

**Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Ali Abdolahinia

**Street address**

Darabad Ave., Bahonar St. (Niavaran)

**City**

Tehran

**Province**

Tehran

**Postal code**

1956944413

**Phone**

+98 21 2712 3000

**Email**

pr.nritld@sbmu.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Shahid Beheshti University of Medical Sciences

**Proportion provided by this source**

80

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Babak Daneshfard

**Position**

Iranian Medicine specialist

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Traditional Medicine

**Street address**

Darabad Ave., Bahonar St. (Niavaran)

**City**

Tehran

**Province**

Tehran

**Postal code**

1956944413

**Phone**

+98 21 2712 3000

**Email**

babakdaneshfard@gmail.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Shahid Beheshti University of Medical Sciences

**Full name of responsible person**

Ali Abdolahinia

**Position**

Iranian Medicine specialist

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Traditional Medicine

**Street address**

Darabad Ave., Bahonar St. (Niavaran)

**City**

Tehran

**Province**

Tehran

**Postal code**

1956944413

**Phone**

+98 21 2712 3000

**Email**

aaliabd@gmail.com

## Person responsible for updating data

### Contact

**Name of organization / entity**

Behdane Baran pharmaceutical company

**Full name of responsible person**

Behnaz Najafi

**Position**

researcher

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

No 13. West Nosrat St. Tohid square.

**City**

Tehran

**Province**

Tehran

**Postal code**

1457785588

**Phone**

+98 21 6657 6805

**Email**

najafi\_b90@yahoo.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available